Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We verified that the oncogenic effect of iASPP on Burkitt lymphoma is TAp63 dependent rather than p53 and confirmed that the interaction between CDK1 and iASPP enhanced the inhibitory effect of iASPP on p53 and TAp63.
|
30105797 |
2018 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used these methods to characterize the p53 mutation in tumor cells of a 53-year-old male suffering from Burkitt's lymphoma.
|
18813817 |
2008 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We selected a group of 16 patients with acute lymphoblastic leukemia (ALL) and Burkitt's lymphoma (BL) in order to investigate the presence of p53 mutations.
|
9407719 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present here genetic data regarding the status of the p53 gene in the Burkitt lymphoma cell line, Raji.
|
1437144 |
1992 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated temporal relationships between ionizing radiation-induced G1 arrest and induction of the p53-regulated genes GADD45, CIP1/WAF1, and MDM2 in a series of Burkitt's lymphoma and lymphoblastoid cell lines that differed in p53 gene status.
|
7757991 |
1995 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified TP53 mutations in MYC+/BCL2+ lymphomas at a frequency intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.
|
24679006 |
2015 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have shown here that in 70% of Burkitt lymphoma cell lines, but not in normal EBV transformed B cell lines, p53 protein is readily detectable by Western blot analysis using either an antibody directed against the 240 epitope or an antibody against wild-type p53.
|
8344493 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also find that the mutational spectrum of p53 in BL differs from that observed in nonlymphoid tumors.
|
1638540 |
1992 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transfection of the wt p53 gene into the p53 mutant and highly tumorigenic BL-41 cell line caused it to acquire wt p53 function and rendered it less tumorigenic in mice.
|
9192833 |
1997 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To discover regulators of mutp53 protein accumulation, we performed a large-scale RNA interference screen in a Burkitt lymphoma cell line model.
|
29653964 |
2018 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2.
|
11360201 |
2001 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This work shows that LMP2A can permit tumorigenesis in the presence of an intact p53 pathway, identifying an important contribution of EBV to BL.
|
19815507 |
2009 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the lack of CD54 by BL cells may provide the background for the mutation of p53 gene to occur which could result in the transformation to a more aggressive phenotype.
|
9172810 |
1996 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that (i) significant differences in the frequency of p53 mutations are present among subtypes of neoplasms derived from the same tissue; (ii) p53 may play a role in tumor progression in B-cell chronic lymphocytic leukemia; (iii) the presence of both p53 loss/inactivation and c-myc oncogene activation may be important in the pathogenesis of Burkitt lymphoma and its leukemic form L3-type B-cell acute lymphoblastic leukemia.
|
2052620 |
1991 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The viral-associated diseases, Adult T-cell Leukemia (ATL) and Burkitt's lymphoma, showed higher p53 mutation frequencies of 24% and 41%, respectively.
|
8580789 |
1995 |
Childhood Burkitt Lymphoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The role of inactivation of tumor-suppressor loci is best exemplified by the frequent inactivation of p53 in Burkitt's lymphoma and by the recurrent deletion of 6q25-q27 and 6q21-q23 in intermediate- and high-grade non-Hodgkin's lymphoma, respectively.
|
8218489 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proportions of tumour cells with accumulation of p53 appeared to correlate with tumour SPF only in EBV DNA positive BLs.
|
1337333 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study assessed the role of the p53 tumor suppressor gene in cell cycle arrest and apoptosis following treatment of Burkitt's lymphoma and lymphoblastoid cell lines with gamma-rays, etoposide, nitrogen mustard, and cisplatin.
|
7954409 |
1994 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The positive case had Burkitt's lymphoma and a p53 missense mutation at codon 273.
|
9450808 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The molecular biological characteristics of Burkitt lymphoma (BL), in addition to the presence of the Epstein-Barr virus (EBV) in some forms, relies on well-characterized alterations, such as MYC translocations and TP53 inactivations.
|
11793449 |
2002 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of p53 was demonstrated in non-T non-B cells and Burkitt's lymphoma cell lines, but neither in two myeloid leukemia cell lines nor in normal lymphoid cells after mitogenic stimulation. p53 expression was demonstrated in 7 cases (2 AML, 5 ALL) but only in ALL cases the percentage of positive of cells was over 20%.
|
1853683 |
1991 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The absence of detectable levels of p53 protein cannot discount the existence of p53 mutations, as is shown by a case of Burkitt's lymphoma in which a nonsense mutation was detected.
|
8219204 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies in eight Burkitt's lymphoma and lymphoblastoid cell lines (four wild-type p53 and four mutant p53 cell lines) revealed that the DNA-damaging agents assayed tended to exhibit less growth inhibition in the mutant p53 cell lines compared to the wild-type p53 cell lines.
|
9563901 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: Targeting MDM4 to alleviate degradation of p53 can be exploited therapeutically across Burkitt lymphoma and other cancers with wild-type p53 harboring 1q gain, the most frequent copy number alteration in cancer.
|
31000522 |
2019 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
|
8402660 |
1993 |